📊 ICCC Key Takeaways
Is Immucell Corp. /DE/ (ICCC) a Good Investment?
ImmuCell demonstrates exceptional financial health with 45% gross margins, 19% operating margins, and strong free cash flow conversion (32.8% FCF margin), supported by conservative leverage (0.30x D/E) and fortress-like liquidity (4.82x current ratio). However, modest revenue growth of 4.3% YoY and low capital returns (6.7% ROE, 4.4% ROA) limit upside potential, suggesting a stable, profitable business lacking significant growth momentum.
ImmuCell’s fundamentals are improving: positive operating income and free cash flow with a solid 41% gross margin and strong liquidity indicate a healthier core business despite a small GAAP loss. Moderate leverage and adequate interest coverage provide runway for scaling; sustaining revenue growth and operating leverage should tip results to consistent profitability.
Immucell Corp. /DE/ Key Strengths (ICCC)
- Exceptional profitability margins (45% gross, 19% operating, 18.7% net) indicating pricing power and operational efficiency
- Outstanding balance sheet with 4.82x current ratio and 0.30x debt-to-equity providing substantial financial flexibility
- Strong free cash flow generation ($3.4M FCF, 32.8% FCF margin) with minimal capital intensity ($177.2K CapEx)
- Strong liquidity (4.26x current, 1.93x quick)
- Positive free cash flow (4.4% margin) and operating income
- Healthy gross margin (41.4%) with moderate leverage (0.34x D/E)
ICCC Stock Risks: Immucell Corp. /DE/ Investment Risks
- Anemic revenue growth of 4.3% YoY is concerning for a diagnostic/biotech company needing scale
- Low return on equity (6.7%) and return on assets (4.4%) suggest inefficient capital deployment or underutilization of asset base
- Small absolute revenue base ($10.4M) limits ability to fund R&D, market expansion, or acquisitions necessary for competitive positioning
- Net losses persist (net margin -3.8%) hurting ROE/ROA
- Modest revenue growth (+4.3% YoY) may limit scale benefits
- Interest coverage only 3.8x; margins sensitive to cost/volume
Key Metrics to Watch
- Revenue growth acceleration and year-over-year trends in top-line
- Free cash flow sustainability and capital allocation decisions
- Return on equity and asset efficiency improvements
- Operating margin and sustained FCF generation
- Revenue growth pace and gross margin stability
Immucell Corp. /DE/ (ICCC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 32.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 4.82x current ratio provides a solid financial cushion.
ICCC Profit Margin, ROE & Profitability Analysis
ICCC vs Healthcare Sector: How Immucell Corp. /DE/ Compares
How Immucell Corp. /DE/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immucell Corp. /DE/ Stock Overvalued? ICCC Valuation Analysis 2026
Based on fundamental analysis, Immucell Corp. /DE/ has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immucell Corp. /DE/ Balance Sheet: ICCC Debt, Cash & Liquidity
ICCC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immucell Corp. /DE/'s revenue has grown significantly by 49% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.26 indicates the company is currently unprofitable.
ICCC Revenue Growth, EPS Growth & YoY Performance
ICCC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.1M | $1.4M | $0.16 |
| Q3 2025 | $5.5M | -$139.7K | $-0.02 |
| Q3 2023 | $4.8M | -$655.1K | $-0.08 |
| Q3 2022 | $4.8M | $147.8K | $-0.02 |
| Q2 2018 | $1.7M | -$218.4K | $-0.05 |
| Q1 2018 | $2.9M | -$168.1K | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immucell Corp. /DE/ Dividends, Buybacks & Capital Allocation
ICCC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immucell Corp. /DE/ (CIK: 0000811641)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ICCC
What is the AI rating for ICCC?
Immucell Corp. /DE/ (ICCC) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 73% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ICCC's key strengths?
Claude: Exceptional profitability margins (45% gross, 19% operating, 18.7% net) indicating pricing power and operational efficiency. Outstanding balance sheet with 4.82x current ratio and 0.30x debt-to-equity providing substantial financial flexibility. ChatGPT: Strong liquidity (4.26x current, 1.93x quick). Positive free cash flow (4.4% margin) and operating income.
What are the risks of investing in ICCC?
Claude: Anemic revenue growth of 4.3% YoY is concerning for a diagnostic/biotech company needing scale. Low return on equity (6.7%) and return on assets (4.4%) suggest inefficient capital deployment or underutilization of asset base. ChatGPT: Net losses persist (net margin -3.8%) hurting ROE/ROA. Modest revenue growth (+4.3% YoY) may limit scale benefits.
What is ICCC's revenue and growth?
Immucell Corp. /DE/ reported revenue of $10.4M.
Does ICCC pay dividends?
Immucell Corp. /DE/ does not currently pay dividends.
Where can I find ICCC SEC filings?
Official SEC filings for Immucell Corp. /DE/ (CIK: 0000811641) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ICCC's EPS?
Immucell Corp. /DE/ has a diluted EPS of $0.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ICCC's fundamental grade?
Based on our AI fundamental analysis in June 2026, Immucell Corp. /DE/ has a A grade with 73% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ICCC stock overvalued or undervalued?
Valuation metrics for ICCC: ROE of 6.7% (sector avg: 15%), net margin of 18.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ICCC's AI grade for 2026?
Our dual AI analysis gives Immucell Corp. /DE/ a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ICCC's free cash flow?
Immucell Corp. /DE/'s operating cash flow is $3.6M, with capital expenditures of $177.2K. FCF margin is 32.8%.
How does ICCC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.7% (avg: 12%), ROE 6.7% (avg: 15%), current ratio 4.82 (avg: 2).